Mild nausea can occur with GLP-1 medications, but nausea becomes more concerning when it is severe, persistent, worsening, or paired with other symptoms
bei Long COVID bekannt geworden sind
The OASIS 4 trial, a 71-week randomised placebo-controlled study, found that participants taking oral semaglutide lost approximately 15% of their body weight on average at the full 25mg dose, compared to around 3% in the placebo group
thus, the PBN may serve an integrating function in the food aversive and avoidant effects of GLP-1R agonism ( Figure 3 )
Some people experience mild symptoms, while others may notice more significant effects on their wellbeing
While taking semaglutide, it generally takes about two weeks to start working in the body